Sigmund H. Hsu

Sigmund H. Hsu

Neurology
929 Gessner Rd
Ste 2410
Houston, TX 77024

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Molecular features of intratumoral hemorrhage in glioblastoma isocitrate dehydrogenase-wildtype.

Molecular features of intratumoral hemorrhage in glioblastoma isocitrate dehydrogenase-wildtype.

Journal: Journal of neuro-oncology
Published: July 13, 2026

Patterns of failure following stereotactic radiosurgery salvage for recurrent high-grade glioma.

Patterns of failure following stereotactic radiosurgery salvage for recurrent high-grade glioma.

Journal: Journal of neuro-oncology
Published: February 04, 2026

Butterfly Glioblastoma: Genetic alterations and outcomes.

Butterfly Glioblastoma: Genetic alterations and outcomes.

Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Published: January 09, 2026

Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents.

Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents.

Journal: Neuro-oncology practice
Published: December 29, 2025

Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.

Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.

Journal: Neuro-oncology advances
Published: October 27, 2025

Stereotactic Radiosurgery Versus Reoperation in Small Surgically Accessible Recurrent Glioblastoma.

Stereotactic Radiosurgery Versus Reoperation in Small Surgically Accessible Recurrent Glioblastoma.

Journal: Neurosurgery
Published: September 01, 2025

Molecular Features of Glioblastoma Isocitrate Dehydrogenase-Wildtype in Extreme Survival Groups After Supramaximal and Maximal Resection.

Molecular Features of Glioblastoma Isocitrate Dehydrogenase-Wildtype in Extreme Survival Groups After Supramaximal and Maximal Resection.

Journal: Neurosurgery
Published: June 02, 2025

Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.

Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.

Journal: Journal of neuro-oncology
Published: March 10, 2025

Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.

Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.

Journal: bioRxiv : the preprint server for biology
Published: March 10, 2025

The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.

The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.

Journal: Cancers
Published: May 22, 2024

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.

Journal: Neuro-oncology advances
Published: February 08, 2024

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report.

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report.

Journal: Oncotarget
Published: May 10, 2023
Showing 1-12 of 25

Last Updated: 09/26/2026